GSK, CureVac team up to develop vaccine against 19 variants



* 150 mln eur deal to develop next-generation vaccines

* GSK to also help produce 100 mln doses of CureVac's vaccine

* GSK has suffered setbacks in COVID-19 vaccine development

By Ludwig Burger

FRANKFURT, Feb 3 (Reuters) - Britain's GlaxoSmithKline GSK.L and German biotech firm CureVac 5CV.DE have teamed up in a 150 million euro ($180 million) deal to develop a COVID-19 vaccine from next year that could target several variants with one shot.

New, more contagious mutations of COVID-19 have emerged in Britain, South Africa and Brazil and while existing vaccines appear to offer some protection against them, there are fears further changes in the virus could evade current shots.

For GSK, the world's largest vaccine maker by sales, the deal marks a fresh attempt to play a major role in fighting the pandemic after a COVID-19 alliance with Sanofi SASY.PA ran into delays and a collaboration with China's Clover Biopharmaceuticals was ended.

GSK, which acquired a 10% stake in CureVac last year, will also support the production of up to 100 million doses of CureVac's first generation COVID-19 vaccine candidate in 2021, the companies said in a joint statement on Wednesday.

A CureVac spokesman said that would firm up group's target to produce up to 300 million doses this year.

Having started mass testing of its vaccine candidate in Europe and Latin America in December, CureVac expects an initial readout from that study in March or April.

CureVac is also collaborating with Bayer BAYGn.DE to speed up development and production of that vaccine.

The German biotech firm is banking on messenger RNA, a cutting-edge genetic technology that has allowed rivals BioNTech BNTX.O and Moderna MRNA.O to lead the COVID-19 vaccine development race.

GSK, while having done early research into mRNA vaccines against various diseases, has so far focused its pandemic response on a more traditional vaccine approach.

It has been providing adjuvants, which are efficacy boosting ingredients, to developers of protein-based vaccines.

GSK, which is scheduled to release 2020 results at 1200 GMT, will pay CureVac 75 million euros upfront, adding another 75 million if certain development milestones are achieved.

($1 = 0.8308 euros)
Reporting by Ludwig Burger. Editing by Kirsti Knolle and Mark Potter

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.